The global hormone replacement therapy market size was valued at USD 21.8 billion in 2019 and is expected to witness a CAGR of 7.7% over the forecast period. Hormone replacement is recommended for replenishing the hormones in the human body when the hormone levels in the body drop as compared to the standard levels required for the proper functioning of the body.
Hormonal imbalance disorders, including menopause, are the key factors driving the market for hormone replacement therapy. The female body undergoes several types of hormonal changes. Hormone levels get altered with growing age, leading to various disorders and diseases.
Certain challenges faced due to hormonal imbalance are weight gain, fatigue, memory decline, low libido, and muscle loss. Menopausal females are the leading population base influencing the market. The average starting age of menopause amongst women is around 45 to 50 years. In menopausal women, the hormonal levels of progesterone & estrogen decrease considerably.
According to the studies conducted by agencies such as the Rose Research, the North American Menopause Society (NAMS), and Therapeutic MD, around one million women in the U.S. are currently opting for hormone replacement therapy and the number is expected to reach around 2.5 million in the near future. The increasing number of women who are about to reach menopause along with the widening of the menopausal window to 40 to 55 years is expected to lead the hormone replacement therapy (HRT) market.
The product segment includes therapies for estrogen, testosterone, human growth hormone, and thyroid hormones. The estrogen hormone replacement therapy segment dominated the overall market for hormone replacement therapy in terms of revenue share in 2019. Estrogen replacement therapy is used in women during post-menopause or hysterectomy and help them maintain the hormonal balance. Estrogen-based products have been studied to generate the largest number of prescriptions thus making it the largest segment.
Human growth hormone therapy is expected to witness the fastest growth over the forecast period owing to the rising incidences of growth deficiencies, particularly in infants. According to a survey organized by the WHO, about 15 million newborns are born premature and approximately 85% of these infants are not fully developed. In adults, the hormone therapy is provided for conditions such as short bowel syndrome and pituitary tumors.Key market players involved in the development of drugs used in these therapies are Roche, Novo Nordisk, Eli Lilly, Pfizer, Merck, and Novartis (Sandoz).
On the bases of the route of administration, the market for hormone replacement therapy is segmented into parenteral, oral tablets, transdermal patches, and others. The parenteral segment dominated the overall market in terms of revenue share in 2019. The oral route of administration is mostly preferred for testosterone drugs. The other segment is inclusive of products such as vaginal creams, implants, vaginal rings, and vaginal tablets.
In the type of disease segment, menopause is expected to be the fastest growing segment over the forecast period from 2020 to 2027. According to the statistics provided by the American Congress of Obstetricians and Gynecologists, around 6,000 women reach menopause daily.
The presence of various branded and generic drugs and increasing awareness among women are anticipated to be the vital impact of rendering drivers. Rising number of women who are about to reach menopause and widening menopausal window from 40 to 55 years is driving the segment.
North America dominated the overall market for hormone replacement therapy in terms of revenue share in 2019. Factors such as innovation in the drug delivery systems, development of new formulations, and rising target population within North America are expected to maintain its dominance over the forecast period. The NIH states that half of the postmenopausal women have used HRT at least once. Asia Pacific, on the other hand, is expected to witness the fastest growth over the forecast period from 2020 to 2027. Increasing awareness levels and rising focus of healthcare providers on the eradication of hormonal deficiencies are expected to boost the growth of the market within the region.
The market is characterized by the increasing number of approvals, expansions through acquisitions, and collaborations. For instance, Mylan Laboratories acquired of Famy Care for USD 750 million in February 2015. Post the acquisition, Mylan undertook the female health business inclusive of the production of hormone replacement drugs, contraceptives, and Intra-Uterine Devices (IUD). The key players in this market for hormone replacement therapy are Abbott Laboratories; Novartis; Pfizer, Inc.; Mylan Laboratories; Merck and Co.; Novo Nordisk; Bayer Healthcare; Eli Lilly; Genentech.
Attribute |
Details |
Base year for estimation |
2019 |
Actual estimates/Historical data |
2016 - 2018 |
Forecast period |
2020 - 2027 |
Market representation |
Revenue in USD Million & CAGR from 2020 to 2027 |
Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
Country scope |
U.S., Canada, U.K., Germany, Japan, China, Brazil, Mexico, South Africa, Saudi Arabia |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors & trends |
15% free customization scope (equivalent to 5 analyst working days) |
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization |
This report forecasts revenue growth at global, regional, country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2027. For the purpose of this study, Grand View Research has segmented the global hormone replacement therapy market report based on product, route of administration, type of disease, and region:
Product Outlook (Revenue, USD Million, 2016 - 2027)
Estrogen Hormone Replacement Therapy
Human Growth Hormone Replacement Therapy
Thyroid Hormone Replacement Therapy
Testosterone Hormone Replacement Therapy
Route of Administration Outlook (Revenue, USD Million, 2016 - 2027)
Oral
Parenteral
Transdermal
Others
Type of Disease Outlook (Revenue, USD Million, 2016 - 2027)
Menopause
Hypothyroidism
Male Hypogonadism
Growth Hormone Deficiency
Others
Regional Outlook (Revenue, USD Million, 2016 - 2027)
North America
U.S.
Canada
Europe
U.K.
Germany
Asia Pacific
Japan
China
Latin America
Brazil
Mexico
Middle East & Africa
South Africa
Saudi Arabia
b. The global hormone replacement therapy market size was estimated at USD 21.8 billion in 2019 and is expected to reach USD 23.5 billion in 2020.
b. The global hormone replacement therapy market is expected to grow at a compound annual growth rate of 7.7% from 2019 to 2027 to reach USD 39.6 billion by 2027.
b. North America dominated the hormone replacement therapy market with a share of around 39% in 2019. This is attributable to the factors such as innovation in the drug delivery systems, development of new formulations, and rising target population within North America.
b. Some of the key players in this market for hormone replacement therapy are Abbott Laboratories; Novartis; Pfizer, Inc.; Mylan Laboratories; Merck and Co.; Novo Nordisk; Bayer Healthcare; Eli Lilly; Genentech.
b. Hormone replacement is recommended for replenishing the hormones in the human body when the hormone levels in the body drop as compared to the standard levels required for the proper functioning of the body.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.
"The quality of research they have done for us has been excellent."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.